Bayer initiates phase I II study of factor VIII gene transfer therapy with BAY-2599023 Dec. 3, 2018 No Comments
Preclinical evaluation of zifaxaban, an oral inhibitor of factor Xa for thromboembolic diseases Nov. 28, 2018 No Comments
Spark Therapeutics to begin phase I/II study of SPK-8016 gene therapy in hemophilia A Nov. 28, 2018 No Comments
Promacta granted FDA approval for first-line SAA and breakthrough therapy designation for H-ARS Nov. 19, 2018 No Comments
FDA approves Hemlibra for prophylaxis in hemophilia A without factor VIII inhibitors Oct. 5, 2018 No Comments
PhaseBio reports promising phase I results with ticagrelor reversal agent PB-2452 Sep. 25, 2018 No Comments
RSS